Edward Dunne
Urology · Washington, DCNPI 1215000575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Astellas Pharma US Inc at 26.5% of the total.
Across 115 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$630
- Sumitomo Pharma America, Inc.$427
- Urovant Sciences Inc$177
- Myovant Sciences Inc.$130
- Tolmar, Inc.$107
- Ferring Pharmaceuticals Inc.$90
- plus $816 from 23 others
What the payments were for
- Food & beverage$2,20093%
- Education$1777%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 24 | $630 |
| Sumitomo Pharma America, Inc. | 29 | $427 |
| Urovant Sciences Inc | 8 | $177 |
| Myovant Sciences Inc. | 6 | $130 |
| Tolmar, Inc. | 4 | $107 |
| Ferring Pharmaceuticals Inc. | 4 | $90 |
| Procept Biorobotics Corporation | 2 | $75 |
| Antares Pharma, Inc. | 3 | $68 |
| Boston Scientific | 3 | $63 |
| Pfizer | 2 | $47 |
| Mission Pharmacal Company | 3 | $47 |
| Metuchen Pharmaceuticals | 3 | $45 |
| Acerus Pharmaceuticals Corporation | 2 | $43 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| Axonics, Inc. | 1 | $41 |
| Blue Earth Diagnostics | 2 | $41 |
| Olympus America Inc. | 2 | $40 |
| Dendreon Pharmaceuticals LLC | 2 | $36 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Bayer | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $25 |
| Immunitybio, Inc. | 1 | $24 |
| Photocure Inc | 1 | $23 |
| Corcept Therapeutics | 1 | $19 |
| Neotract Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Accord Healthcare, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
How this compares
$2,377 in reported general payments places this provider in the 55th percentile of 47 urology providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 141 | $144,296 |
| OrgovyxRelugolix | 28 | $74,330 |
| MyrbetriqMirabegron | 41 | $46,460 |
| Tamsulosin Hcl | 430 | $8,362 |
| Dutasteride | 137 | $6,096 |
| Finasteride | 180 | $4,104 |
| Potassium Citrate ErPotassium Citrate | 25 | $3,473 |
| Silodosin | 25 | $2,784 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $2,237 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 63 | $1,177 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $624 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $549 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $469 |
| CefuroximeCefuroxime Axetil | 22 | $265 |
| Cefdinir | 16 | $217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $427 | $218,626169 claims |
| Astellas Pharma US IncMyrbetriq | $630 | $46,46041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.